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Over the past 20 years the annual number of reports on extrapulmonary symptoms during
Mycoplasma (M.) pneumoniae disease has increased. Clinical and epidemiological data in-
dicate that symptoms from the skin and mucous membranes, from the central nervous system,
from the heart, and perhaps from other organs as well are not quite uncommon manifestations
of M. pneumoniae disease. Reports on unusual courses of the disease have also accumulated,
including cases of severe respiratory symptoms, sometimes seen in patients with underlying
disease or with a concomitant viral infection. Serious extrapulmonary manifestations have
been common in fatal cases of M. pneumoniae disease.
Some observations and experimental data on these manifestations and on the possible
pathogenic mechanisms are dealt with. The conclusion is that such mechanisms are still largely
unknown.
Mycoplasma (M.) pneumoniae is a common respiratory tract pathogen that
generally produces a mild self-limited disease characterized by cough, malaise,
myalgia, and headache. Lung infiltrates seen by X-ray are often accompanied by
minimal or no physical findings, but a severe pneumonia may develop. Tracheo-
bronchitis and pneumonia are the most common reasons for the patient to seek
medical care. Complications are generally considered to be rare [1].
CLINICAL MANIFESTATIONS
Over the past 20 years an annually increasing number of unusual and severe
clinical pictures of M. pneumoniae disease have been described, involving both the
respiratory tract and other organ systems. Many of these symptoms that were
described as rare complications in the 'sixties might well today achieve the rank of
not quite uncommon manifestations. This achievement would depend on the proof
that the non-respiratory symptoms have the same etiology as the classical respiratory
symptoms of the disease. Or, there should be a significant agreement between the
non-respiratory symptoms and the disease in respect of age, sex, course of illness,
and epidemiology. This seems to be the case in several patients with symptoms from
the skin and mucous membranes, with symptoms from the central nervous system
(CNS), and with affection of the heart and perhaps other organs as well. Also,
various autoimmune phenomena seem to be well-established manifestations of the
disease [2-8].
COMPLICATIONS
Complications of M. pneumoniae disease such as unusual and severe courses of
illness have been reported. They seem to occur predominantly in cases with involve-
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All rights of reproduction in any form reserved.ment of multiple organ systems, and the patients are generally older than those who
have the classical pneumonia. Sequelae from the CNS and the heart belong to the
most serious complications [8,9].
Complications may also arise within the respiratory tract, such as fulminant lobar
pneumonia mimicking severe bacterial pneumonia, or such as acute diffuse alveolitis
[10-12]. Abscess and cavity formation have been described, as well as large pleural
effusions. Also cases of fulminant evolution into diffuse interstitial fibrosis have
been reported [13-19]. Underlying diseases such as cancer, diabetes, chronic heart
disease, and similar conditions may result in a complicated course of the M.
pneumoniae infection [14,20,21].
Concomitant viral infections, especially such that may cause an acute immune
suppression, have been reported in up to 18 percent of M. pneumoniae-diseased pa-
tients [8]. Caution should be exercised when the serodiagnosis of a viral infection is
made during an M. pneumoniae infection, because of the non-specific B-cell
mitogenic potency of this organism [22], a potency which it shares with some
viruses. If such mixed infections do occur frequently, it may be difficult to deter-
mine whether extrapulmonary symptoms are caused by one or the other infection, or
whether both may have mutually complicated the course of illness.
In the acute phase of an M. pneumoniae infection, blood lymphocytes may show
a decreased response to PPD in vitro, as shown by Biberfeld and Sterner [23]. This
depression of cell-mediated immunity was shown by Mogensen and co-workers [24]
to be active also against other microbial antigens likeEscherichia coli, Staphylococ-
cus aureus, Bordetellapertussis, and Candida albicans. These findings may be rele-
vant to M. pneumoniae disease complicated by other infections.
Reports on fatal cases are relatively few, but they will probably increase with the
growing acknowledgement of severe, unusual, and complicated courses of the
disease. To my knowledge, 20 fatal cases have been described in more or less detail
in the literature [4,18,19,25-38], and additional fatal cases have been mentioned in
other contexts. The overall impression is that, in addition to the pneumonia,
manifestations from other organ systems contributed to the fatal outcome of the M.
pneumoniae disease. In five of the 20 cases there had been CNS symptoms, in four
peri- or myocarditis, and in eight coagulation disturbances. It is noteworthy that
seven of the patients had received steroids. The median age of the 20 patients was
32.5 years (range 3 to 71), and the male: female ratio was 2.3:1. These cases serve to
demonstrate the potential malignancy of M. pneumoniae.
EXTRAPULMONARY MANIFESTATIONS:
OBSERVATIONS AND EXPERIMENTAL DATA
During theten-year period from 1968 to 1977, we received clinical informations of
1,867 patients who had a serologically diagnosed M. pneumoniae infection. 10.8
percent had symptoms from the skin and/or mucous membranes, and 7 percent had
symptoms from the CNS. The incidence of cases with these extrapulmonary symp-
toms in each trimester occurred in rather close parallel to the incidence of all
seropositive specimens received during the period (Fig. 1). The relatively high fre-
quency and the concurrence with the infection during major outbreaks indicate that
these extrapulmonary symptoms are true manifestations ofM. pneumoniae disease.
The median age ofall neurological patients was ten years. The last three years of this
material encompassed 998 patients with M. pneumoniae infection. There were 24
cases, or 2.4 percent, ofeither myocarditis, pericarditis, or acute myocardial infarc-
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FIG. 1. Incidenceof cases with symptoms
from the skin and/or mucous membranes
and of cases with symptoms from the CNS
among 1,867 patients with serological indi-
cation of M. pneumoniae infection (lower
graph), compared with the number of anti-
M. pneumoniae plus cold agglutinin posi-
tive specimens received quarterly through
ten years (upper graph).
tion. Although 18 of the cases occurred in the high-incidence year 1975, the period
was too short for an epidemiological evaluation [39].
Neurological complications have been described in seven of 102 patients
hospitalized with a M. pneumoniae infection [4] while the corresponding Finnish
figures were 4.8 percent of 560 patients [8]. In a prospective study we found among
patients with acute, febrile, non-bacterial CNS affection 5 percent who had
serological evidence of a current M. pneumoniae infection [7].
Cardiac symptoms during M. pneumoniae disease may be more common when
looked for as described by Sands and co-workers [40] who found both light and
severe cases of carditis in 8.5 percent of hospitalized M. pneumoniae-infected pa-
tients. Ponka [9] reported that 4.5 percent of 560 patients with M. pneumoniae in-
fection had carditis, and his epidemiological data point to an etiological role of this
mycoplasma. Carre and co-workers [41] advance the hypothesis that M.
pneumoniae infection may reveal or aggravate a latent coronary affection. This
association was not confirmed in a recent paper by Ponka [42].
Other non-respiratory tract symptoms seen during M. pneumoniae disease include
those from the gastrointestinal tract. Mardh and Ursing [31] have described six cases
of pancreatitis following pneumonia due to this infection. Diabetes mellitus
developed in two of these, and one case was fatal. In this context it should be noted
that Finnish workers have questioned the specificity of CF antibodies to M.
400-
Quarterly number ot
anti-M.pneum. positive and
cold-aggi. positive sera
463pneumoniae in acute pancreatitis [43]. Hematological symptoms in M. pneumoniae
disease are rare. Both hemolytic anemia and disturbance of coagulation mechanism
have been reported. Signs of disseminated intravascular coagulation have been
described, especially in fatal cases. Also arthritis is a rare complication in M.
pneumoniae disease [1-3, 8].
PATHOGENESIS OF EXTRAPULMONARY MANIFESTATIONS:
OBSERVATIONS AND EXPERIMENTAL DATA
The extrapulmonary manifestations ofM. pneumoniae disease may be a result of
the presence of the pathogen in the target organ or organ system. The paucity of
reports on isolation of M. pneumoniae from skin eruptions and CNS favors the
hypothesis of an indirect effect of the microorganism in most cases [44-47]. So far,
however, no neurotoxin has been demonstrated for this mycoplasma. In several
cases a tendency to hypercoagulation has been reported, and intravascular clotting
in the CNS cannot be excluded as a pathogenic mechanism [8].
The variety ofneurological clinical pictures which may be seen inM. pneumoniae-
infected patients, both with and without respiratory tract symptoms, and the dif-
ferent time relation to onset of illness and to antibody development may give the
impression that more than one mechanism is operating [7]. The possibility of an
indirect immune mechanism was advanced when Biberfeld found complement-
fixing (CF) antibodies to brain tissue antigen in patients with M. pneumoniae infec-
tion. However, not all patients had neurological manifestations [48]. In a prospec-
tive study of patients with neurological symptoms, we found CF antibodies to brain
antigen at a high titer in three of ten patients with a current M. pneumoniae infec-
tion, while in 82 neurological patients without evidence of this infection no an-
tibodies to brain were detected [7].
By investigation of sera from more than 100 patients with M. pneumoniae infec-
tion, we found that CF antibodies to brain tissue antigen were present mainly
together with high titer CF antibodies to M. pneumoniae. When two matched
groups of M. pneumoniae patients were compared, selected in twos by the same
anti-M. pneumoniae titer, one with and one without neurological symptoms, an-
tibodies to brain were found significantly more often among the neurological pa-
tients (Table 1) [39].
We fractionated sera by density gradient ultracentrifugation and tested the IgM
and IgG classes for antibodies to brain tissue and to M. pneumoniae. In two of four
TABLE 1
Complement-Fixing Antibodies to Human Brain Tissue in Two Groups of Patients
with Positive Anti-M. pneumoniae Test
Patients with
Number Median Respiratory Symptoms
CNS Symptoms of Age Male/ Bronchitis Antibrain
Present Patients (range) Female Pneumonia or URI None Titer
YES 49 23 31/18 37 6 6 19b
(1-79)
NO 49 23 23/26 42 3 4 8b
(2-70)
,,URI, upper respiratory tract infection
b2p = 0.023
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TABLE 2
Absorption of Human and Rabbit Sera with M. Pneumoniae and Human Brain Tissue
Complement Fixation
Titer of Antibodies to
Absorbed
Serum with Brain M. pneum.
From 24-year- 0 256 5,000
old female M. pneumoniae 64 64
with pneumonia Human brain < 16 2,000
Pool from four 0 512 4,000
rabbits given M. pneumoniae <8 <8
live M. pneum.
intravenously Human brain <8 2,000
patients with meningitis the anti-brain antibodies were found both in the IgM and
the IgG fractions. In the other two patients antibodies to brain were found in the
IgM class only. In sera from seven pneumonia patients without neurological symp-
toms, antibodies to brain were found exclusively in the IgM fractions. Sera from all
these patients, both with and without neurological symptoms, had high titers of an-
tibodies to M. pneumoniae both in the IgM and IgG fractions. Antibrain antibodies
were detected between one and 14 days after onset of neurological symptoms, on the
average on day 6 [39]. The results are in accordance with fractionation experiments
of Biberfeld, who also looked for these antibodies in the spinal fluid of two
neurological patients with negative results [2,48].
We found that absorption of patients' sera with M. pneumoniae antigen reduced
the titer of antibodies both to the homologous antigen and to brain tissue antigen.
However, absorption with brain tissue only removed antibrain antibodies but did
not significantly reduce the titer of antibodies to M. pneumoniae. Similar results
were obtained by absorption of sera from rabbits immunized with M. pneumoniae
(Table 2) [39]. This partial cross-reaction between antigens of human brain and M.
pneumoniae has also been shown by Biberfeld [2], and it could be further
demonstrated when the antigens were used as immunogens in rabbits. As shown in
Table 3, subcutaneous injections of human brain tissue with adjuvant gave rise to
TABLE 3
Antibodies in Rabbits Vaccinated with Human Brain Tissue or with M. pneumoniae
Complement Fixation
Number GM Titer of Antibodies to
of Vaccinated
Rabbits with Brain M. pneum.
5 Human brain + 388 < 16
FCA subcutaneously
2 Killed M. pneum. 8 4,000 + FCA subcutaneously 8
4 Live M. pneum. 1,145 >4,000
intravenously
GM, Geometric mean
FCA, Freund's complete adjuvant
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antibodies to brain but not to M. pneumoniae, and killed mycoplasmas with adju-
vant injected by the same route resulted in formation of antibodies to this antigen
but not to human brain. However, when rabbits were given live M. pneumoniae in-
travenously, they produced antibodies both to M. pneumoniae and to human brain
tissue. The results from giving this live vaccine may reflect the natural M.
pneumoniae infection in man; none of the four rabbits showed any neurological
symptoms [39]. The pathogenic role of these antibodies is not known. This is true
also of immune complexes which were demonstrated by Biberfeld and Norberg in
the blood during the acute phase of the disease [49].
Another neuropathogenic activity might be one mediated by lymphocytes. When
testing blood lymphocytes from patients with M. pneumoniae infection and
neurological symptoms Mogensen and Lind [50] found that responses to stimulation
with M. pneumoniae antigen in vitro tended to be low or normal in patients who had
no pleocytosis in the spinal fluid or no pulmonary infiltrates, while responses were
high when either pleocytoses or a pneumonia was present. The high responses were
comparable to those obtained with lymphocytes from patients with classical M.
pneumoniae pneumonia. The low lymphocyte response which corresponded to lack
of lymphocyte accumulations might be due to an effect of antigen-specific sup-
pressor T-lymphocytes.
CONCLUDING REMARKS
The pathogenic mechanisms of the various manifestations and complications of
M. pneumoniae disease are still largely unknown. The endeavor to unveil these
mechanisms should include attempts to demonstrate the specific antigen in the target
organs and tissues. It might prove profitable to investigate further the possible
pathogenic role of subpopulations of lymphocytes and their products in M.
pneumoniae disease. As a basis of these investigations, the serological criteria of the
diagnosis of this disease should be re-evaluated.
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